<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene L18F;D80A;D215G;L242del;A243del;K417N;E484K;N501Y;D614G;A701V literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.L18F;D80A;D215G;L242_A243del;K417N;E484K;N501Y;D614G;A701V</span> literature reference collection</h1>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) â€“ heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.<br/> (<a href="https://doi.org/10.21203/rs.3.rs-226857/v1" class="lit_link">Skelly et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
